Phase I and pharmacologic study of BNP7787, a novel chemoprotector in patients with advanced non-small cell lung cancer

PURPOSE: We conducted a phase I trial of BNP7787 (disodium 2,2′-dithio-bis-ethane sulfonate, Tavocept™), a novel chemoprotective and antitumor enhancing agent administered in combination with paclitaxel and cisplatin. The primary aim was to determine a safe and potentially efficacious BNP7787 dose f...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Noriyuki, Negoro, Shunichi, Hausheer, Frederick, Nakagawa, Kazuhiko, Matsui, Kaoru, Kudoh, Shinzoh, Takeda, Koji, Yamamoto, Nobuyuki, Yoshimura, Naruo, Ohashi, Yasuo, Fukuoka, Masahiro
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2010
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043260/
https://www.ncbi.nlm.nih.gov/pubmed/20473611
http://dx.doi.org/10.1007/s00280-010-1340-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3043260/
https://www.ncbi.nlm.nih.gov/pubmed/20473611
http://dx.doi.org/10.1007/s00280-010-1340-y

Ejemplares similares